NO20005223L - Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon - Google Patents

Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon

Info

Publication number
NO20005223L
NO20005223L NO20005223A NO20005223A NO20005223L NO 20005223 L NO20005223 L NO 20005223L NO 20005223 A NO20005223 A NO 20005223A NO 20005223 A NO20005223 A NO 20005223A NO 20005223 L NO20005223 L NO 20005223L
Authority
NO
Norway
Prior art keywords
inflammatory bowel
bowel disease
composition
acetylglucosamine
colon
Prior art date
Application number
NO20005223A
Other languages
Norwegian (no)
Other versions
NO20005223D0 (en
Inventor
Simon Murch
Ian W French
Original Assignee
Glucogenics Pharmaceuticals In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA1999/000218 external-priority patent/WO1999053929A1/en
Application filed by Glucogenics Pharmaceuticals In filed Critical Glucogenics Pharmaceuticals In
Publication of NO20005223D0 publication Critical patent/NO20005223D0/en
Publication of NO20005223L publication Critical patent/NO20005223L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Oppfinnelsen angår en ny sammensetning og en ny fremgangsmåte til å behandle inflammatorisk tarmsykdom (IBD). Mer spesielt angår denne oppfinnelsen en ny sammensetning som inneholder N-acetylglukosamin (NAG) som et aktivt IBD- behandlende middel og en farmasøytisk egnet bærer, og en fremgangsmåte til å administrere sammensetningen til colon for å behandle IBD hos en person som lider av IBD. En sammensetning for å behandle inflammatorisk tarmsykdom hos en pasient som lider av inflammatorisk tarmsykdom omfatter: (a) en terapeutisk mengde av N- acetylglukosamin; og (b) en farmasøytisk akseptabel bærer, tilpasset til å bli administrert til colon hos nevnte pasient.This invention relates to a novel composition and method for treating inflammatory bowel disease (IBD). More particularly, this invention relates to a novel composition containing N-acetylglucosamine (NAG) as an active IBD-treating agent and a pharmaceutically suitable carrier, and to a method of administering the composition to the colon to treat IBD in a person suffering from IBD. A composition for treating inflammatory bowel disease in a patient suffering from inflammatory bowel disease comprises: (a) a therapeutic amount of N-acetylglucosamine; and (b) a pharmaceutically acceptable carrier adapted to be administered to the colon of said patient.

NO20005223A 1998-04-17 2000-10-17 Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon NO20005223L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
PCT/CA1999/000218 WO1999053929A1 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine

Publications (2)

Publication Number Publication Date
NO20005223D0 NO20005223D0 (en) 2000-10-17
NO20005223L true NO20005223L (en) 2000-11-20

Family

ID=4162337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005223A NO20005223L (en) 1998-04-17 2000-10-17 Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon

Country Status (8)

Country Link
EP (1) EP1071432A1 (en)
JP (1) JP2002512195A (en)
CA (1) CA2234936C (en)
CZ (1) CZ20003846A3 (en)
HU (1) HUP0101514A3 (en)
IL (1) IL139072A0 (en)
NO (1) NO20005223L (en)
PL (1) PL343634A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918452T3 (en) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Hemostatic compositions and therapeutic regimens
KR101098581B1 (en) 2009-01-09 2011-12-26 서울대학교산학협력단 Composition for Improving Inflammatory Disorder Using ABH Antigen
US8858964B2 (en) 2010-04-15 2014-10-14 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
BR112017011198A2 (en) * 2014-11-26 2018-06-26 Evonik Röhm Gmbh pharmaceutical or nutraceutical composition with resistance against the influence of ethanol.
KR102104507B1 (en) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same

Also Published As

Publication number Publication date
JP2002512195A (en) 2002-04-23
IL139072A0 (en) 2001-11-25
CA2234936C (en) 2004-06-29
CZ20003846A3 (en) 2002-03-13
CA2234936A1 (en) 1999-10-17
NO20005223D0 (en) 2000-10-17
EP1071432A1 (en) 2001-01-31
PL343634A1 (en) 2001-08-27
HUP0101514A2 (en) 2001-11-28
HUP0101514A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
NO20052348L (en) Treatment of hemorrhagic shock
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
NO20033617L (en) Procedure for the treatment of diabetes mellitus
MY120279A (en) Use of a celecoxib composition for fast pain relief
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
EA200501496A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
NO20003051L (en) Method of administration of AspB28 human insulin
SG148850A1 (en) Methods of treating vascular disease
WO2003105763B1 (en) Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
NO20044562L (en) Methods for treating bowel disease
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP0957925A4 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
ATE305469T1 (en) SULFONIC ACID OR SULFONYLAMINO-N-(HETEROARALKYL)-AZAHETEROCYCLYL MIDDLE COMPOUNDS
NO20024924L (en) Use of bradycardial substances in the treatment of myocardial diseases in connection with hypertrophy and new drug combinations
NO20055390L (en) Thorium-227 for use in radiotherapy in soft tissue diseases
NO20005223L (en) Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon
BR0008443A (en) Inhibitors of branched-chain amino acid-dependent aminotranspheres and their use in the treatment of diabetic retinopathy
BR0201974A (en) Pharmaceutical composition for treating sleep disorders
NO20042758L (en) Procedure for treating a patient requiring analgesia.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
EP1447090B8 (en) Use of hyaluronidase for preventing and treating cardiovascular diseases
NO984974L (en) Means that improve pulmonary circulation
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
BR0111790A (en) Pharmaceutical formulation, method for prophylactic or therapeutic treatment of a patient suffering from or susceptible to atherosclerosis, use of a pharmaceutical formulation, and kit of parts.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application